Faculty

Institution

Unit

Venue

Amy Moran

Associate Professor of Cell Developmental and Cancer Biology

Oregon Health & Science University

Affiliations

Biostatistics Shared Resources

Institute Of Knight Cancer

OHSU School of Medicine

Cancer Early Detection Advanced Research Center (Cedar)

Department Of Cell, Developmental And Cancer Biology

Department Of Dermatology

Department Of Otolaryngology - Head And Neck Surgery

Division Of Oncological Sciences

Center Of Cancer Early Detection Advanced Research (Cedar)

Institute Of Knight Cancer

Center Of Knight Cancer

Department Of Cell Biology

Department of Medicine

Division Of Hematology/Medical Oncology

Flow Cytometry Shared Resource

Institute Of Knight Cancer

Cancer Early Detection Advanced Research Center (Cedar)

Institute Of Knight Cancer

Division Of Oncological Sciences

Institute Of Knight Cancer

Department Of Cell, Developmental And Cancer Biology

Institute Of Knight Cancer

Division Of Hematology/Medical Oncology

Institute Of Knight Cancer Insitute

Institute Of University Knight Cancer

Department Of Otolaryngology - Head And Neck Surgery

Molecular Biology of Head and Neck Cancer

Oregon Health & Science University

Amy Moran is currently serving as a Biostatistics Shared Resources Associate Professor of Cell Developmental and Cancer Biology at Oregon Health & Science University.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Amy Moran

Oregon Health & Science University

Associate Professor of Cell Developmental and Cancer Biology

You can click a keyword to filter the displayed items

immunology immune responses cell biology cancer immunotherapy immunotherapy cellular therapy cellular immune responses pharmacology oncology cancer cells therapeutic targets prostate cancer immunomodulation urology cell research cancer research medicinal research cancer treatment molecular cancer experimental medicine immune checkpoint inhibitors cancer immunosurveillance cancer biology oncogenes anti-cancer agents t-regulatory cell endocrine-related cancers pharmacotherapy drug targeting prostatic disease adaptive immune system hormonal receptor metastasis cancer discovery cell transplantation genitourinary cancers enzyme inhibition cancer care tumor targeting clinical immunology tolerance induction androgen receptor blockade sequence analysis genome sequencing population genomics breast oncology single-cell sequencing data androgen receptor activity phase ii study inconvenient variable mammalian biology nature peptides antiviral research experimental biology knockout mice genome analysis microarray data analysis therapeutic vaccines endocrine oncology biomarker target treatment development cancer growth cancer genetics immunologic mechanisms inkt cell development antigen-independent differentiation phenotype-associated subpopulations tnfrs ox40 t-cell receptor affinity thymic development treatment response gastrointestinal microbiota immunotherapy expands preclinical immunotherapy experiments exacerbates autoimmune arthritis gynecologic oncology pathology cell death surgical oncology dermatology carcinogenesis autoimmunity breast cancer tumor biology translational research cell signaling surgical pathology jama oncology immunity (medicine) biomarkers radiation oncology translational medicine molecular diagnostics systems biology ovarian cancer cancer letter tumor microenvironment bladder cancer molecular medicine cancer imaging histopathology medicine clinical proteomics leukemia

Notable Scholarly Works

Notable Federal Grants

Collaborators

Abstract 1294: Deciphering Single-Cell Heterogeneity and Cellular Ecosystem Dynamics During Prostate Cancer Progression.. Cancer Research (2026)

prostate cancer progressioncancer cellstumor biologycell biologysingle-cell analysismolecular cancerprostate cancercellular ecosystem dynamicsabstract 1294urologytumor heterogeneitycancer biology

Genomic and Molecular Associations With Preoperative Immune Checkpoint Inhibition in Patients With Stage III Clear Cell Renal Cell Carcinoma. Cancers (2026)

molecular associationskidney cancercancer immunotherapyimmunologyimmunotherapymolecular cancergenitourinary cancerscancer discoveryjama oncologycancer genomicsurologyimmune checkpoint inhibitors

Igf1 Modulates Lesional Skin Inflammation in Checkpoint Inhibitor-Induced Lichen Planus. bioRxiv (Cold Spring Harbor Laboratory) (2026)

inflammationcell deathimmunologycell biologyimmune mediatorsdermatologydermatological treatmentimmune responsescutaneous biologyautoimmune diseases

Androgen Receptor Activity Tunes Cd8 T Cell Effector Responses 4316. The Journal of Immunology (2025)

endocrine-related cancerscell signalingimmunologycell biologyimmunotherapycellular therapyimmune responsescellular immune responsessignal transductionendocrinologycell researchreceptorshormonal receptor

Elevated Tumor-Associated Androgen Receptor Activity Correlates With Poor Immune Infiltration and Immunotherapy Response Across Cancer Types. Cancer Research Communications (2025)

pathologyendocrine-related cancersimmunotherapy responsepoor immune infiltrationcancer immunotherapyimmunologyimmunotherapycancer immunosurveillancecancer typescancer cellscancer lettertumor microenvironment

Supplementary Figure 4 From Androgen Receptor Inhibition Increases Mhc Class I Expression and Improves Immune Response in Prostate Cancer. (2025)

Lisa N. ChesnerFanny PolessoJulie N. GraffJessica E. HawleyAlexis K. SmithArian LundbergRajdeep DasTanushree ShenoyMartin SjöströmFaming ZhaoYa-Mei HuSimon LinderWilliam S. ChenReed M. HawkinsRaunak ShresthaXiaolin ZhuAdam FoyeHaolong LiLisa M. KimMegha BhallaThomas O’loughlinDuygu Kuzuoglu-OzturkJunjie T. HuaMichelle L. BaduraScott WilkinsonShana Y. TrostelAndries M. BergmanDavide RuggeroCharles G. DrakeAdam G. SowalskyLawrence FongMatthew R. CooperbergWilbert ZwartXiangnan GuanAlan AshworthZheng XiaDavid A. QuigleyLuke A. GilbertFelix Y. FengAmy E. Moran

immune responsesimmunologyprostate cancer

683 Investigating Sex and Gender-Related Differences in Immunotherapy Treatment Effects: The Insite Study. Regular and Young Investigator Award Abstracts (2024)

insite studysexual and reproductive healthimmunologysex researchimmunotherapy treatment effectsimmunotherapyinvestigating sexallergyimmunity (medicine)medicinesexual medicineexperimental medicinesex differencesimmunosuppressive therapysexual healthclinical immunologyreproductive immunology

Abstract 5270: Androgen Receptor Blockade in Macrophages Primes Nlrp3 Inflammasome-Mediated Phagocytosis and Tumor Clearance in Advanced Prostate Cancer. Cancer Research (2024)

Kiranj ChaudagarSrikrishnan RameshbabuShenglin MeiTaghreed HirzYa-Mei HuAnna ArgulianBrian LabadieKunal DesaiSam GrimaldoDoga KahramangilRishikesh NairSabina DSouzaDylan ZhouRaymond ChenJordan ShafranMayme LoydZheng XiaDavid SykesAmy MoranAkash Patnaik

drug targetinganti-cancer agentsadvanced prostate cancerimmunologypharmacologycancer immunotherapycancer researchtumor clearancecancer cellscancer treatmentandrogen receptor blockademedicinal researchprostate cancercellular therapyurologycancer managementcancer carecancer biologyinflammasome-mediated phagocytosiscancer imagingclinical researchoncology

Androgen Receptor Activity Inversely Correlates With Immune Cell Infiltration and Immunotherapy Response Across Multiple Cancer Lineages. bioRxiv (Cold Spring Harbor Laboratory) (2024)

oncogenesendocrine-related cancersimmune cell infiltrationcancer immunotherapyimmunologycell biologyimmunotherapymultiple cancer lineagescancer immunosurveillancecancer cellsandrogen receptor activitytumor microenvironmenthormonal receptor

Androgen Receptor Inhibition Increases Mhc Class I Expression and Improves Immune Response in Prostate Cancer. Cancer Discovery (2024)

oncogenescancer cellsendocrine-related cancerscancer immunotherapyimmunologyprostate cancerprostatic diseasecancer researchimmune responsescancer discoverymolecular biologyurologycancer geneticsoncologycancer biology

1
2
3
4
5
6
10 / page

Amy Moran

Associate Professor of Cell Developmental and Cancer Biology

Oregon Health & Science University

Affiliations

Biostatistics Shared Resources

Institute Of Knight Cancer

OHSU School of Medicine

Cancer Early Detection Advanced Research Center (Cedar)

Department Of Cell, Developmental And Cancer Biology

Department Of Dermatology

Department Of Otolaryngology - Head And Neck Surgery

Division Of Oncological Sciences

Center Of Cancer Early Detection Advanced Research (Cedar)

Institute Of Knight Cancer

Center Of Knight Cancer

Department Of Cell Biology

Department of Medicine

Division Of Hematology/Medical Oncology

Flow Cytometry Shared Resource

Institute Of Knight Cancer

Cancer Early Detection Advanced Research Center (Cedar)

Institute Of Knight Cancer

Division Of Oncological Sciences

Institute Of Knight Cancer

Department Of Cell, Developmental And Cancer Biology

Institute Of Knight Cancer

Division Of Hematology/Medical Oncology

Institute Of Knight Cancer Insitute

Institute Of University Knight Cancer

Department Of Otolaryngology - Head And Neck Surgery

Molecular Biology of Head and Neck Cancer

Oregon Health & Science University

Amy Moran is currently serving as a Biostatistics Shared Resources Associate Professor of Cell Developmental and Cancer Biology at Oregon Health & Science University.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Amy Moran

Oregon Health & Science University

Associate Professor of Cell Developmental and Cancer Biology

You can click a keyword to filter the displayed items

Notable Scholarly Works

Notable Federal Grants

Collaborators

Abstract 1294: Deciphering Single-Cell Heterogeneity and Cellular Ecosystem Dynamics During Prostate Cancer Progression.. Cancer Research (2026)

prostate cancer progressioncancer cellstumor biologycell biologysingle-cell analysismolecular cancerprostate cancercellular ecosystem dynamicsabstract 1294urologytumor heterogeneitycancer biology

Genomic and Molecular Associations With Preoperative Immune Checkpoint Inhibition in Patients With Stage III Clear Cell Renal Cell Carcinoma. Cancers (2026)

molecular associationskidney cancercancer immunotherapyimmunologyimmunotherapymolecular cancergenitourinary cancerscancer discoveryjama oncologycancer genomicsurologyimmune checkpoint inhibitors

Igf1 Modulates Lesional Skin Inflammation in Checkpoint Inhibitor-Induced Lichen Planus. bioRxiv (Cold Spring Harbor Laboratory) (2026)

inflammationcell deathimmunologycell biologyimmune mediatorsdermatologydermatological treatmentimmune responsescutaneous biologyautoimmune diseases

Androgen Receptor Activity Tunes Cd8 T Cell Effector Responses 4316. The Journal of Immunology (2025)

Elevated Tumor-Associated Androgen Receptor Activity Correlates With Poor Immune Infiltration and Immunotherapy Response Across Cancer Types. Cancer Research Communications (2025)

Supplementary Figure 4 From Androgen Receptor Inhibition Increases Mhc Class I Expression and Improves Immune Response in Prostate Cancer. (2025)

immune responsesimmunologyprostate cancer

683 Investigating Sex and Gender-Related Differences in Immunotherapy Treatment Effects: The Insite Study. Regular and Young Investigator Award Abstracts (2024)

Abstract 5270: Androgen Receptor Blockade in Macrophages Primes Nlrp3 Inflammasome-Mediated Phagocytosis and Tumor Clearance in Advanced Prostate Cancer. Cancer Research (2024)

Androgen Receptor Activity Inversely Correlates With Immune Cell Infiltration and Immunotherapy Response Across Multiple Cancer Lineages. bioRxiv (Cold Spring Harbor Laboratory) (2024)

Androgen Receptor Inhibition Increases Mhc Class I Expression and Improves Immune Response in Prostate Cancer. Cancer Discovery (2024)

1
2
3
4
5
6
10 / page